ClinTec International, a Windsor, U.K.- based contract research organization (CRO) has formed a co-development partnership with Dr. Reddy's Laboratories, a Hyderabad, India-based pharmaceutical company. The two companies have agreed to begin co-development of DRF 1042, a topoisomerase inhibitor that has shown potential as an anti-cancer treatment.
AstraZeneca Opens First Phase I Unit in U.S.
Pharmaceutical giant AstraZeneca has opened its first clinical pharmacological unit (CPU) in the U.S., in Wilmington, Del. The facility is located at the Penn Presbyterian Medical Center, part of the University of Pennsylvania Health Care System and is capable of conducting phase I trials in any of the company's therapeutic areas. It will be AstraZeneca's fifth CPU worldwide, with units in Sweden and the U.K.
